logo
NFL widows, caregivers say CTE study minimizes their pain

NFL widows, caregivers say CTE study minimizes their pain

Globe and Mail8 hours ago

Dozens of widows and other caregivers for former NFL players diagnosed with CTE say a published study is insulting and dismissive of their experience living with the degenerative brain disease that has been linked to concussions and other repeated head trauma common in contact sports like football.
An open letter signed by the players' wives, siblings and children says the study published in the May 6 issue of Frontiers in Psychology suggests their struggles caring for loved ones was due to 'media hype' about chronic traumatic encephalopathy, rather than the disease itself. The implication that 'caregiver concerns are 'inevitable' due to 'publicity' is callous, patronizing, and offensive,' they said.
'The burden we experienced did not happen because we are women unable to differentiate between our lived experience and stories from TV or newspaper reports,' they wrote in the letter. 'Our loved ones were giants in life, CTE robbed them of their futures, and robbed us of our futures with them. Please don't also rob us of our dignity.'
The pushback was led by Dr. Eleanor Perfetto, herself a medical researcher and the widow of former Steelers and Chargers end Ralph Wenzel, who developed dementia and paranoia and lost his ability to speak, walk and eat. He was first diagnosed with cognitive impairment in 1999 — six years before Pittsburgh center Mike Webster's CTE diagnosis brought the disease into the mainstream media.
'My own experience, it just gave a name to what I witnessed every day. It didn't put it in my head,' Perfetto said in an interview with The Associated Press. 'It gave it a name. It didn't change the symptoms.'
The study published last month asked 172 caregivers for current and former professional football players 'whether they believed their partner had 'CTE.'' Noting that all of the respondents were women, Perfetto questioned why their experiences would be minimized.
'Women run into that every day,' she said. 'I don't think that's the only factor. I think the motivation is to make it seem like this isn't a real issue. It's not a real disease. It's something that people glommed on to because they heard about it in the media.'
Hopes for study 'quickly turned to disappointment'
The letter was posted online on Monday under the headline, 'NFL Caregivers to Harvard Football Player Health Study: Stop Insulting Us!' It had more than 30 signatures, including family of Hall of Famers Nick Buoniconti and Louis Creekmur.
It praises the study for examining the fallout on loved ones who weathered the violent mood swings, dementia and depression that can come with the disease. The letter says the study gets it wrong by including what it considers unsupported speculation, such as: 'Despite being an autopsy-based diagnosis, mainstream media presentations and high-profile cases related to those diagnosed postmortem with CTE may have raised concerns among living players about CTE.'
The letter said these are 'insulting conclusions that were not backed by study evidence.'
'Rather than exploring the lived experiences of partners of former athletes, they instead implied the partners' anxiety was caused by watching the news ... as if the media is to blame for the severe brain atrophy caused by CTE in our loved ones,' they wrote.
Study authors Rachel Grashow and Alicia Whittington said in a statement provided to the AP that the goal of their research is 'to support NFL families, especially those caring for affected players or grieving for lost loved ones.'
'We regret if any of our work suggested otherwise,' they said. 'Our intent was not to minimize CTE — a disease that is far too real — but to point out that heightened attention to this condition can intensify existing concerns, and that symptoms attributed to CTE may, in some cases, stem from other treatable conditions that also deserve recognition and care.'
But Perfetto feared the study was part of a trend to downplay or even deny the risks of playing football. After years of denials, the NFL acknowledged in 2016 a link between football and CTE and eventually agreed to a settlement covering 20,000 retired players that provided up to $US4-million for those who died with the disease. (Because it requires an examination of the brain tissue, CTE currently can only be diagnosed posthumously.)
'Why would a researcher jump to 'the media' when trying to draw conclusions out of their data, when they didn't collect any information about the media,' Perfetto told the AP. 'To me, as a researcher, you draw the implications from the results and you try to think of, practically, 'Why you come to these conclusions? Why would you find these results?' Well, how convenient is it to say that it was the media, and it takes the NFL off the hook?'
'By players, for players'
The caregivers study is under the umbrella of the Football Players Health Study at Harvard University, a multifaceted effort 'working on prevention, diagnostics, and treatment strategies for the most common and severe conditions affecting professional football players.' Although it is funded by the NFL Players Association, neither the union nor the league has any influence on the results or conclusions, the website says.
'The Football Players Health Study does not receive funding from the NFL and does not share any data with the NFL,' a spokesperson said.
Previous research — involving a total of more than 4,700 ex-players — is on topics ranging from sleep problems to arthritis. But much of it has focused on brain injuries and CTE, which has been linked to contact sports, military combat and other activities that can involve repetitive head trauma.
When he died with advanced CTE in 2012 at age 69, Wenzel could no longer recognize Perfetto and needed help with everyday tasks like getting dressed or getting out of bed — an added problem because he was a foot taller and 100 pounds heavier than she is. 'When he died, his brain had atrophied to 910 grams, about the size of the brain of a 1-year-old child,' the letter said.
Former Auburn and San Diego Chargers running back Lionel 'Little Train' James, who set the NFL record for all-purpose yards in 1985, was diagnosed with dementia at 55 and CTE after he died at 59.
'Treatable conditions were not the reason Lionel went from being a loving husband and father to someone so easily agitated that his wife and children had to regularly restrain him from becoming violent after dodging thrown objects,' the letter said. 'They were not likely to be the driving force behind his treatment-resistant depression, which contributed to alcoholism, multiple stays in alcohol rehabilitation treatment centers, arrests, suicidal ideation, and ultimately, his commitment to a mental institution.'
Kesha James told the AP that she would disable the car to keep her husband from driving drunk. She said she had never spoken of her struggles but chose to tell her story now to remove the stigma associated with the players' late-in-life behavior — and the real-life struggles of their caregivers.
'I have videos that people probably would not believe,' James said. 'And I'll be honest with you: It is nothing that I'm proud of. For the last three years I've been embarrassed. I'm just going public now because I do want to help bring awareness to this — without bringing any shame to me and my kids — but just raise the awareness so that no other family can experience what I did.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NFL widows, caregivers say CTE study minimizes their pain
NFL widows, caregivers say CTE study minimizes their pain

Globe and Mail

time8 hours ago

  • Globe and Mail

NFL widows, caregivers say CTE study minimizes their pain

Dozens of widows and other caregivers for former NFL players diagnosed with CTE say a published study is insulting and dismissive of their experience living with the degenerative brain disease that has been linked to concussions and other repeated head trauma common in contact sports like football. An open letter signed by the players' wives, siblings and children says the study published in the May 6 issue of Frontiers in Psychology suggests their struggles caring for loved ones was due to 'media hype' about chronic traumatic encephalopathy, rather than the disease itself. The implication that 'caregiver concerns are 'inevitable' due to 'publicity' is callous, patronizing, and offensive,' they said. 'The burden we experienced did not happen because we are women unable to differentiate between our lived experience and stories from TV or newspaper reports,' they wrote in the letter. 'Our loved ones were giants in life, CTE robbed them of their futures, and robbed us of our futures with them. Please don't also rob us of our dignity.' The pushback was led by Dr. Eleanor Perfetto, herself a medical researcher and the widow of former Steelers and Chargers end Ralph Wenzel, who developed dementia and paranoia and lost his ability to speak, walk and eat. He was first diagnosed with cognitive impairment in 1999 — six years before Pittsburgh center Mike Webster's CTE diagnosis brought the disease into the mainstream media. 'My own experience, it just gave a name to what I witnessed every day. It didn't put it in my head,' Perfetto said in an interview with The Associated Press. 'It gave it a name. It didn't change the symptoms.' The study published last month asked 172 caregivers for current and former professional football players 'whether they believed their partner had 'CTE.'' Noting that all of the respondents were women, Perfetto questioned why their experiences would be minimized. 'Women run into that every day,' she said. 'I don't think that's the only factor. I think the motivation is to make it seem like this isn't a real issue. It's not a real disease. It's something that people glommed on to because they heard about it in the media.' Hopes for study 'quickly turned to disappointment' The letter was posted online on Monday under the headline, 'NFL Caregivers to Harvard Football Player Health Study: Stop Insulting Us!' It had more than 30 signatures, including family of Hall of Famers Nick Buoniconti and Louis Creekmur. It praises the study for examining the fallout on loved ones who weathered the violent mood swings, dementia and depression that can come with the disease. The letter says the study gets it wrong by including what it considers unsupported speculation, such as: 'Despite being an autopsy-based diagnosis, mainstream media presentations and high-profile cases related to those diagnosed postmortem with CTE may have raised concerns among living players about CTE.' The letter said these are 'insulting conclusions that were not backed by study evidence.' 'Rather than exploring the lived experiences of partners of former athletes, they instead implied the partners' anxiety was caused by watching the news ... as if the media is to blame for the severe brain atrophy caused by CTE in our loved ones,' they wrote. Study authors Rachel Grashow and Alicia Whittington said in a statement provided to the AP that the goal of their research is 'to support NFL families, especially those caring for affected players or grieving for lost loved ones.' 'We regret if any of our work suggested otherwise,' they said. 'Our intent was not to minimize CTE — a disease that is far too real — but to point out that heightened attention to this condition can intensify existing concerns, and that symptoms attributed to CTE may, in some cases, stem from other treatable conditions that also deserve recognition and care.' But Perfetto feared the study was part of a trend to downplay or even deny the risks of playing football. After years of denials, the NFL acknowledged in 2016 a link between football and CTE and eventually agreed to a settlement covering 20,000 retired players that provided up to $US4-million for those who died with the disease. (Because it requires an examination of the brain tissue, CTE currently can only be diagnosed posthumously.) 'Why would a researcher jump to 'the media' when trying to draw conclusions out of their data, when they didn't collect any information about the media,' Perfetto told the AP. 'To me, as a researcher, you draw the implications from the results and you try to think of, practically, 'Why you come to these conclusions? Why would you find these results?' Well, how convenient is it to say that it was the media, and it takes the NFL off the hook?' 'By players, for players' The caregivers study is under the umbrella of the Football Players Health Study at Harvard University, a multifaceted effort 'working on prevention, diagnostics, and treatment strategies for the most common and severe conditions affecting professional football players.' Although it is funded by the NFL Players Association, neither the union nor the league has any influence on the results or conclusions, the website says. 'The Football Players Health Study does not receive funding from the NFL and does not share any data with the NFL,' a spokesperson said. Previous research — involving a total of more than 4,700 ex-players — is on topics ranging from sleep problems to arthritis. But much of it has focused on brain injuries and CTE, which has been linked to contact sports, military combat and other activities that can involve repetitive head trauma. When he died with advanced CTE in 2012 at age 69, Wenzel could no longer recognize Perfetto and needed help with everyday tasks like getting dressed or getting out of bed — an added problem because he was a foot taller and 100 pounds heavier than she is. 'When he died, his brain had atrophied to 910 grams, about the size of the brain of a 1-year-old child,' the letter said. Former Auburn and San Diego Chargers running back Lionel 'Little Train' James, who set the NFL record for all-purpose yards in 1985, was diagnosed with dementia at 55 and CTE after he died at 59. 'Treatable conditions were not the reason Lionel went from being a loving husband and father to someone so easily agitated that his wife and children had to regularly restrain him from becoming violent after dodging thrown objects,' the letter said. 'They were not likely to be the driving force behind his treatment-resistant depression, which contributed to alcoholism, multiple stays in alcohol rehabilitation treatment centers, arrests, suicidal ideation, and ultimately, his commitment to a mental institution.' Kesha James told the AP that she would disable the car to keep her husband from driving drunk. She said she had never spoken of her struggles but chose to tell her story now to remove the stigma associated with the players' late-in-life behavior — and the real-life struggles of their caregivers. 'I have videos that people probably would not believe,' James said. 'And I'll be honest with you: It is nothing that I'm proud of. For the last three years I've been embarrassed. I'm just going public now because I do want to help bring awareness to this — without bringing any shame to me and my kids — but just raise the awareness so that no other family can experience what I did.'

Anti‑Obesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP‑1 Incretins and Uptake of Oral Treatments
Anti‑Obesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP‑1 Incretins and Uptake of Oral Treatments

Globe and Mail

time9 hours ago

  • Globe and Mail

Anti‑Obesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP‑1 Incretins and Uptake of Oral Treatments

Mordor Intelligence has published a new report on the Anti‑Obesity Drugs Market, offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction Mordor Intelligence, in its latest anti‑obesity drugs market report, forecasts the market to reach from USD 25.93 billion in 2025 to USD 100.97 billion by 2030, advancing at a 31.24 % CAGR. The anti-obesity drugs market focuses on medications developed to aid in weight loss and manage obesity related conditions. Obesity is a chronic, relapsing condition associated with several health issues, including type 2 diabetes, cardiovascular diseases, sleep apnea, and certain cancers. As global obesity rates rise driven by sedentary lifestyles, poor dietary habits, and genetic factors, there is growing demand for medical interventions beyond lifestyle changes and bariatric surgery. Key Trends The anti‑obesity drugs landscape is being reshaped by several important developments: 1. GLP‑1 receptor agonists gaining dominance Gut‑hormone incretins, primarily GLP‑1 agonists, are set to expand at 33.15 % CAGR through 2030. Their strong efficacy in reducing weight and favorable safety profiles have led major pharmaceutical companies to scale up production and secure lifecycle extensions for these agents 2. Oral formulations on the rise Although injectables account for 81.3 % of the 2024 market share, oral anti‑obesity drugs are projected to grow at an impressive 36.6 % CAGR through 2030. This surge reflects patient preference for pill-based therapies and investment in oral GLP‑1 pills by developers. 3. Prescription segment maintains leadership Prescription drugs commanded 84.2 % of the anti‑obesity drugs market in 2024. Over‑the‑counter options trail behind but are gaining traction, with the prescription category still growing at a 32.56 % CAGR through 2030 4. Digital pharmacies unlocking access Retail pharmacies held 54.05 % of the market in 2024, but online pharmacies are catching up. They are expected to grow at a 34.75 % CAGR, spurred by e‑commerce ease and expanding reimbursement support. 5. Asia‑Pacific emerging fast North America remains the largest market with a 65.9 % revenue share in 2024. However, Asia‑Pacific is advancing at a robust 33.65 % CAGR, driven by rising healthcare spending and expanding obesity awareness. Market Segmentation The anti‑obesity drugs market can be segmented in multiple ways, enabling stakeholders to identify growth pockets and tailor strategies. By Mechanism of Action Peripherally acting drugs led revenue in 2024, capturing 60.10% of the market. These medications act within the digestive system, such as fat‑absorption inhibitors and appetite suppressants, reducing energy uptake or signalling fullness. Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through 2030. These therapies mimic or enhance gut hormones to regulate appetite and blood sugar. Prescription drugs held a dominant share at 84.20% in 2024. This category includes clinically validated medications with regulatory backing and reimbursement frameworks. Over‑the‑counter (OTC) drugs occupy a smaller share but are gradually gaining influence through ease of access and increasing consumer trust. By Route of Administration Injectables commanded 81.30% of the market in 2024, driven by the widespread use of injectable GLP‑1 therapies known for their strong efficacy. Oral drugs are emerging as the most dynamic segment, projected to grow at a 36.60% CAGR from 2025 to 2030, reflecting a clear patient trend toward pills over injections. By Distribution Channel Retail pharmacies made up 54.05% of market revenues in 2024, remaining the standard way for patients to obtain anti‑obesity medications. Online pharmacies are fast growing (projected 34.75% CAGR to 2030), propelled by telehealth, convenient home delivery, and evolving reimbursement policies. By Geography North America was the largest regional market, securing a 65.90% share in 2024. This dominance stems from advanced healthcare systems, approval frameworks, and strong payer support. Asia‑Pacific is the fastest expanding region, with a projected CAGR of 33.65%. Growth drivers include rising obesity awareness, healthcare investments, and broader pharmaceutical access. Key Players Roche Roche is a global pharmaceutical company that has recently entered the anti-obesity drugs market. The company has secured licensing agreements for potential weight loss candidates, signaling its interest in expanding its portfolio to include obesity treatments. Roche's expertise in biotechnology and commitment to addressing unmet medical needs position it as a noteworthy participant in the obesity care landscape. GlaxoSmithKline (GSK) GSK is a multinational healthcare company involved in the development of various therapeutic areas, including obesity. The company is exploring the potential of amylin analogs and other hormonal agents for weight management. GSK's research initiatives aim to provide patients with alternative treatment options and contribute to the advancement of obesity care. Novo Nordisk Novo Nordisk is a leading global healthcare company specializing in diabetes and obesity care. The company has developed several GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), which have shown significant efficacy in weight management. Novo Nordisk continues to invest in research and development to expand its portfolio of anti-obesity medications and enhance patient outcomes. Currax Pharmaceuticals Currax Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for obesity. Through strategic acquisitions, such as obtaining rights to Contrave, Currax has expanded its presence in the anti-obesity drugs market. The company's focus on addressing obesity-related health issues aligns with the growing demand for effective weight management therapies. Eli Lilly and Company Eli Lilly is another major player in the anti-obesity drugs market, known for its innovative therapies. The company's GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), has demonstrated promising results in clinical trials for weight loss. Eli Lilly's commitment to obesity care is reflected in its ongoing research efforts and strategic partnerships aimed at advancing treatment options for patients. Conclusion The anti‑obesity drugs market is entering a transformative era, with expected growth from USD 25.93 billion in 2025 to USD 100.97 billion by 2030 at a 31.24 % CAGR. This growth is fuelled by the powerful clinical outcomes of GLP‑1 agonists, innovation in oral formulations, expanded access via online pharmacies, and increasing attention to obesity as a chronic disease. While North America remains the dominant market, Asia‑Pacific's rapidly growing demand offers substantial opportunities. Competition is intensifying, as established pharmaceutical companies and biotechs alike race to advance next generation therapies and diversify distribution channels. As market dynamics evolve, stakeholders should monitor: • Progress of oral GLP‑1 candidates and dual/triple‑agonists like CagriSema • Regulatory approvals and reimbursement pathways, especially in emerging regions • Competitive responses from lifecycle extensions to partnerships and acquisitions • Supply chain robustness and accessibility, particularly amid supply constraints for high‑demand drugs In sum, the anti‑obesity drugs market is poised for significant expansion, with transformative treatments and shifting delivery models likely to reshape global healthcare delivery and patient outcomes. Industry Related Reports Ozempic Market : The Ozempic Market Report is segmented by region, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report provides both value (in USD) and volume (in units) for each of these segments. Japan Oral Anti-Diabetic Drug Market: The Japan Oral Anti-Diabetic Drug Market Report is segmented by drug types, including Biguanides, Alpha-Glucosidase Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, and others, as well as end users, such as Hospitals/Clinics, Personal/Home Care Settings, and others. The report provides market size and forecasts for each segment in terms of value (USD). Get More Insights: Anti-Snoring Market: The Anti-Snoring Devices Market report segments the industry by device type, including Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) Devices, and other device types. It also segments by surgical procedures such as Uvulopalatopharyngoplasty (UPPP), Somnoplasty, Pillar Procedure, Tonsillectomy, Radiofrequency Palatoplasty, and more. Additionally, the report covers geographical segmentation. About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@

Is Increased Focus on Hypersonic Tech Opening New Doors for Rocket Lab?
Is Increased Focus on Hypersonic Tech Opening New Doors for Rocket Lab?

Globe and Mail

time9 hours ago

  • Globe and Mail

Is Increased Focus on Hypersonic Tech Opening New Doors for Rocket Lab?

In recent years, the rapid development and adoption of hypersonic technology across industries, from aerospace and defense to space exploration, have opened new growth avenues for Rocket Lab USA RKLB, a key player in hypersonic testing with its HASTE launch system. With commercial firms and government agencies ramping up investments in advanced hypersonic systems to bolster space access and national security, RKLB remains well-positioned to capitalize on this accelerating technological shift. Notably, Rocket Lab's HAEST (Hypersonic accelerator suborbital test electron) is a suborbital testbed launch vehicle that provides reliable, high-cadence flight test opportunities needed to boost hypersonic and suborbital system technology development. In April 2025, Rocket Lab secured a contract from Kratos Defense to conduct a full-scale hypersonic test flight for the U.S. Department of Defense. Additionally, RKLB's HASTE platform has been included in two major defense frameworks — the $46 billion Enterprise-Wide Agile Acquisition Contract with the U.S. Air Force and the UK Ministry of Defence's £1 billion ($1.3 billion) Hypersonic Technologies & Capability Development Framework. These programs allow Rocket Lab to compete for launch and engineering services in advancing hypersonic technologies. The inclusion across both U.S. and UK initiatives underscores the growing demand for HASTE in defense testing and is likely to significantly boost Rocket Lab's future revenue stream. While HASTE has not yet won any purely commercial contract, its demonstrated reliability and cadence in the defense sector may soon open doors to non-defense payload opportunities. Other Stocks Focusing on Hypersonic As increased investment in hypersonic technology has become a global trend lately, with nations like the United States, the United Kingdom, and China significantly boosting funding for research and development in this tech, other stocks like Lockheed Martin LMT and RTX Corp. RTX are also indulging in advanced hypersonic technology developments. Notably, Lockheed Martin has been developing highly advanced hypersonic technology for the past 60 years. To this end, the company is currently working in partnership with DARPA, the U.S. Air Force, the U.S. Army, and the U.S. Navy to transition hypersonic concepts to operational reality. LMT's Conventional Prompt Strike is a hypersonic boost-glide missile currently under development, which boasts the capability to provide longer range, shorter flight times, and high survivability against enemy defenses. On the other hand, RTX is working across its business and domains to move advanced hypersonic capabilities from creation to testing and into the hands of warfighters at top speed. RTX is currently involved in the design of the Hypersonic Attack Cruise Missile, which leverages Northrop Grumman's scramjet propulsion to travel at more than five times the speed of sound and cover vast distances in minutes. The U.S. Air Force currently expects this missile to be operational by fiscal 2027. The Zacks Rundown for RKLB Shares of RKLB have surged 467.2% in the past year compared with the industry 's 40.9% growth. The company's shares are trading at a premium on a relative basis, with its forward 12-month Price/Sales being 17.85X compared with its industry's average of 9.65X. The Zacks Consensus Estimate for RKLB's 2025 and 2026 earnings has improved over the past 60 days. RKLB currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Rocket Lab Corporation (RKLB): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store